Literature DB >> 30373824

Cell-autonomous requirement of TDP-43, an ALS/FTD signature protein, for oligodendrocyte survival and myelination.

Jia Wang1, Wan Yun Ho1, Kenneth Lim1, Jia Feng1, Greg Tucker-Kellogg2, Klaus-Armin Nave3, Shuo-Chien Ling4,5,6.   

Abstract

TDP-43 aggregates in neurons and glia are the defining pathological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), raising the possibility of glial damage in the disease pathogenesis. However, the normal physiological functions of TDP-43 in glia are largely unknown. To address how TDP-43 may be required for oligodendroglial functions we selectively deleted TDP-43 in mature oligodendrocytes in mice. Although mice with TDP-43 deleted in oligodendrocytes are born in an expected Mendelian ratio, they develop progressive neurological phenotypes leading to early lethality accompanied by a progressive reduction in myelination. The progressive myelin reduction is likely due to a combination of the cell-autonomous RIPK1-mediated necroptosis of mature oligodendrocytes and the TDP-43-dependent reduction in the expression of myelin genes. Strikingly, enhanced proliferation of NG2-positive oligodendrocyte precursor cells within the white matter, but not the gray matter, was able to replenish the loss of mature oligodendrocytes, indicating an intrinsic regeneration difference between the gray and white matter oligodendrocytes. By contrast, there was no loss of spinal cord motor neurons and no sign of denervation at the neuromuscular synapses. Taken together, our data demonstrate that TDP-43 is indispensable for oligodendrocyte survival and myelination, and loss of TDP-43 in oligodendrocytes exerts no apparent toxicity on motor neurons.

Entities:  

Keywords:  TDP-43; amyotrophic lateral sclerosis; frontotemporal dementia; necroptosis; oligodendrocyte

Mesh:

Substances:

Year:  2018        PMID: 30373824      PMCID: PMC6243235          DOI: 10.1073/pnas.1809821115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  58 in total

Review 1.  Myelination of the nervous system: mechanisms and functions.

Authors:  Klaus-Armin Nave; Hauke B Werner
Journal:  Annu Rev Cell Dev Biol       Date:  2014       Impact factor: 13.827

Review 2.  Small molecule probes for cellular death machines.

Authors:  Ying Li; Lihui Qian; Junying Yuan
Journal:  Curr Opin Chem Biol       Date:  2017-06-16       Impact factor: 8.822

3.  Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice.

Authors:  Lien-Szu Wu; Wei-Cheng Cheng; C-K James Shen
Journal:  J Biol Chem       Date:  2012-06-20       Impact factor: 5.157

4.  Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease.

Authors:  Sukriti Nag; Lei Yu; Ana W Capuano; Robert S Wilson; Sue E Leurgans; David A Bennett; Julie A Schneider
Journal:  Ann Neurol       Date:  2015-04-22       Impact factor: 10.422

Review 5.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

6.  Gamma motor neurons survive and exacerbate alpha motor neuron degeneration in ALS.

Authors:  Melanie Lalancette-Hebert; Aarti Sharma; Alexander K Lyashchenko; Neil A Shneider
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-07       Impact factor: 11.205

7.  RIPK1 mediates a disease-associated microglial response in Alzheimer's disease.

Authors:  Dimitry Ofengeim; Sonia Mazzitelli; Yasushi Ito; Judy Park DeWitt; Lauren Mifflin; Chengyu Zou; Sudeshna Das; Xian Adiconis; Hongbo Chen; Hong Zhu; Michelle A Kelliher; Joshua Z Levin; Junying Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-13       Impact factor: 11.205

8.  Loss of TDP-43 causes age-dependent progressive motor neuron degeneration.

Authors:  Yohei Iguchi; Masahisa Katsuno; Jun-ichi Niwa; Shinnosuke Takagi; Shinsuke Ishigaki; Kensuke Ikenaka; Kaori Kawai; Hirohisa Watanabe; Koji Yamanaka; Ryosuke Takahashi; Hidemi Misawa; Shoichi Sasaki; Fumiaki Tanaka; Gen Sobue
Journal:  Brain       Date:  2013-02-28       Impact factor: 13.501

9.  Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia.

Authors:  David J Irwin; Corey T McMillan; EunRan Suh; John Powers; Katya Rascovsky; Elisabeth M Wood; Jon B Toledo; Steven E Arnold; Virginia M-Y Lee; Vivianna M Van Deerlin; John Q Trojanowski; Murray Grossman
Journal:  Neurology       Date:  2014-07-03       Impact factor: 9.910

10.  RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS.

Authors:  Yasushi Ito; Dimitry Ofengeim; Ayaz Najafov; Sudeshna Das; Shahram Saberi; Ying Li; Junichi Hitomi; Hong Zhu; Hongbo Chen; Lior Mayo; Jiefei Geng; Palak Amin; Judy Park DeWitt; Adnan Kasim Mookhtiar; Marcus Florez; Amanda Tomie Ouchida; Jian-bing Fan; Manolis Pasparakis; Michelle A Kelliher; John Ravits; Junying Yuan
Journal:  Science       Date:  2016-08-05       Impact factor: 47.728

View more
  23 in total

Review 1.  Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes.

Authors:  Katherine E Prater; Caitlin S Latimer; Suman Jayadev
Journal:  Glia       Date:  2021-09-24       Impact factor: 7.452

Review 2.  The Essential Role of Epigenetic Modifications in Neurodegenerative Diseases with Dyskinesia.

Authors:  Zhipeng Qi; Jiashuo Li; Minghui Li; Xianchao Du; Lei Zhang; Shuang Wang; Bin Xu; Wei Liu; Zhaofa Xu; Yu Deng
Journal:  Cell Mol Neurobiol       Date:  2021-08-12       Impact factor: 4.231

3.  Lipid Metabolism Is Dysregulated in the Motor Cortex White Matter in Amyotrophic Lateral Sclerosis.

Authors:  Gemma L Sadler; Katherine N Lewis; Vinod K Narayana; David P De Souza; Joel Mason; Catriona McLean; David G Gonsalvez; Bradley J Turner; Samantha K Barton
Journal:  Metabolites       Date:  2022-06-17

4.  Loss of TDP-43 in astrocytes leads to motor deficits by triggering A1-like reactive phenotype and triglial dysfunction.

Authors:  Audrey Yi Tyan Peng; Ira Agrawal; Wan Yun Ho; Yi-Chun Yen; Ashley J Pinter; Jerry Liu; Qi Xuan Cheryl Phua; Katrianne Bethia Koh; Jer-Cherng Chang; Emma Sanford; Jodie Hon Kiu Man; Peiyan Wong; David H Gutmann; Greg Tucker-Kellogg; Shuo-Chien Ling
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-30       Impact factor: 11.205

5.  Stage-specific control of oligodendrocyte survival and morphogenesis by TDP-43.

Authors:  Dongeun Heo; Jonathan P Ling; Gian C Molina-Castro; Abraham J Langseth; Ari Waisman; Klaus-Armin Nave; Wiebke Möbius; Phil C Wong; Dwight E Bergles
Journal:  Elife       Date:  2022-03-21       Impact factor: 8.713

Review 6.  The Potential Contribution of Dysfunctional RNA-Binding Proteins to the Pathogenesis of Neurodegeneration in Multiple Sclerosis and Relevant Models.

Authors:  Cole D Libner; Hannah E Salapa; Michael C Levin
Journal:  Int J Mol Sci       Date:  2020-06-27       Impact factor: 5.923

7.  TDP-43 proteinopathy in Theiler's murine encephalomyelitis virus infection.

Authors:  Katsuhisa Masaki; Yoshifumi Sonobe; Ghanashyam Ghadge; Peter Pytel; Raymond P Roos
Journal:  PLoS Pathog       Date:  2019-02-11       Impact factor: 6.823

Review 8.  Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment.

Authors:  Tereza Filipi; Zuzana Hermanova; Jana Tureckova; Ondrej Vanatko; And Miroslava Anderova
Journal:  J Clin Med       Date:  2020-01-18       Impact factor: 4.241

9.  Cryo-EM structures of four polymorphic TDP-43 amyloid cores.

Authors:  Qin Cao; David R Boyer; Michael R Sawaya; Peng Ge; David S Eisenberg
Journal:  Nat Struct Mol Biol       Date:  2019-06-24       Impact factor: 15.369

10.  RNA-binding protein altered expression and mislocalization in MS.

Authors:  Katsuhisa Masaki; Yoshifumi Sonobe; Ghanashyam Ghadge; Peter Pytel; Paula Lépine; Florian Pernin; Qiao-Ling Cui; Jack P Antel; Stephanie Zandee; Alexandre Prat; Raymond P Roos
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.